Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone food effect and dose proportionality in healthy volunteers
NCT03664453Phase 1Completed
- Sponsor
- Biogen
- Start
- Oct 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of omaveloxolone in Friedreich's ataxia (FA) (3 arms), sponsored by Biogen. Primary endpoints: Maximum Observed Concentration at 20 days and Area Under Curve at 20 days. Started Oct 2018; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03664453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664453.